Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial - Li, Kezhen; Chen, Jing; Hu, Yingjie; Wang, Yan-Zhou; Shen, Yuanming; Chen, Gang; Peng, Wenju; Fang, Zixuan; Xia, Bairong; Chen, Xiaojun; Song, Kun; Wang, Yingmei; et al. (The lancet oncology, 2024)
Keywords: Adverse events; Biomarkers; Cancer therapies; Cervical cancer; Chemoradiotherapy; Chemotherapy; Cisplatin; Contraindications; Gynecology; Hematology, Oncology, and Palliative Medicine; Hysterectomy; Immune checkpoint inhibitors; Immunotherapy; Laboratories; Leukopenia; Lymphatic system; Lymphopenia; Neutropenia; Obstetrics; Paclitaxel; Patients; Radiation therapy; Response rates; Risk factors; Solid tumors; Surgery; Toxicity; Tumors; United States--US; China